Top Stories
-
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
Topic
-
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.
Topic
-
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
-
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
